Page last updated: 2024-09-04

celastrol methyl ester and Osteoporosis

celastrol methyl ester has been researched along with Osteoporosis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chen, R; Hou, L; Li, X; Liang, J; Lin, X; Liu, Q; Su, Y; Wu, Z; Xu, F; Yang, X; Zhao, J	1

Other Studies

1 other study(ies) available for celastrol methyl ester and Osteoporosis

Article	Year
Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways. Drug design, development and therapy, 2021, Volume: 15 Topics: Animals; Bone Resorption; Cell Survival; Cells, Cultured; Female; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; NF-kappa B; Osteoclasts; Osteoporosis; Ovariectomy; Pentacyclic Triterpenes; Protective Agents; Transcription Factor RelA	2021

Article

Year

Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways.

Drug design, development and therapy, 2021, Volume: 15

Topics: Animals; Bone Resorption; Cell Survival; Cells, Cultured; Female; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; NF-kappa B; Osteoclasts; Osteoporosis; Ovariectomy; Pentacyclic Triterpenes; Protective Agents; Transcription Factor RelA

2021